Readings

SES # Topics READINGS
Fall 2005
1

Authorship

Speaker

Dr. Julie Ingelfinger, Professor of Pediatrics, Harvard Medical School and Deputy Editor, New England Journal of Medicine

Drazen, Jeffrey M., and Gregory D. Curfman. “On Authors and Contributors.” N Engl J Mcd 347 (2002): 55.

Kempers, R. D. “Ethical issues in biomedical publications.” Fertil Steril 77 (2002): 883-888.

2

Ethical and Professional Conduct Issues in Engineering Breakthrough Medical Technologies

Speaker

John Abele, founder and Chairman of Boston Scientific Corporation

Hashimoto, H., et al. “The diffusion of medical technology, local conditions, and technology re-invention: A comparative case study on coronary stenting.” Health Policy (February 10, 2006). [e-pub ahead of print.]

Libeer, J. C. “Role of external quality assurance schemes in assessing and improving quality in medical laboratories.” Clin Chim Acta 309 (2001): 173-177.

3

HST Graduate Program Design and Administration

Speaker 

Dr. Sangeeta Bhatia, an HST Graduate and Recent Addition to the Faculty at HST

National Academy of Sciences. Committee on Science, Engineering, and Public Policy. On Being a Scientist: Responsible Conduct in Research. Washington, DC: National Academy Press, 1995.
4

Case Studies on Funding Ethical Issues in Academia and the Clinic

Speaker

Dr. John Parrish, Chairman of Dermatology for the Harvard Teaching Hospitals, Founder and Former Director of the Wellman Labs for PhotoMedicine, and Founder and Director of the Center for the Integration of Medicine and Innovative Technology (CIMIT)

Chadwick, R., and U. Schuklenk. “Sleeping with the enemy? Where to draw the line on research funding?” Bioethics 19 (2005): iii-iv.

Cichy, K. A. “Ethical implications of for-profit corporate sponsorship of research.” SRA J 22 (1990): 23-27.

5

Ethical Dilemmas Associated with Drug Development for Small Target Groups

Speaker

Dave Fleming, Senior VP of Genzyme

Gericke, C. A., A. Riesberg, and R. Busse. “Ethical issues in funding orphan drug research and development.” J Med Ethics 31 (2005): 164-168.

Hughes, D. A., B. Tunnage., and S. T. Yeo. “Drugs for exceptionally rare diseases: do they deserve special status for funding?” QJM 98 (2005): 829-836.

6

Ethical Issues Related to Clinical Research in High Stress Environments

Speaker 

Kris Olson, MD

Bjerneld, M., et al. “Perceptions of work in humanitarian assistance: interviews with returning Swedish health professionals.” Disaster Manag Response 2 (2004): 101-108.
Spring 2006
7

Ethics of Closed-loop Medical Control Systems

Speaker

Prof. John Guttag, Senior Professor of Electrical Engineering and Computer Science at MIT

Shoeb, A., et al. “Patient-specific seizure onset detection.” Epilepsy Behav 5 (2004): 483-498.
8

Ethics of Pharmaceutical Post-market Surveillance

Speaker

Dr. Frank Douglas, Executive Director of the Center for Biomedical Innovation Management, MIT

Abraham, J., and C. Davis. “A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.” Soc Sci Med 61 (2005): 881-892.
9

Ethical Considerations in Accelerating Medical Technologies

Speaker

Dr. Wendy Everett, President of the New England Healthcare Institute (NEHI)

 
10

Ethics of Live-sustaining Biomedical Engineering Design

Speaker

Dr. David Lederman, Founder and Former Chairman of ABIOMED

 
11

The Good Works Project and Ethical Conduct of Research

Speaker

Dr. Howard Gardner, John H. and Elisabeth A. Hobbs Professor of Cognition and Education at the Harvard Graduate School of Education

 
12 The Ethics of Genetic Screening for Therapeutic Procedures